A sponsor will have to demonstrate success with "with several consecutive patients with different bespoke therapies" to ...

The recommendation makes a second drug available in England for treating transthyretin amyloidosis with cardiomyopathy.

The Ontario Hereditary Cancer Research Network is assembling a province-wide registry for research-consented individuals who have received hereditary cancer gene testing.

Investigators at Boston institutions believe the regimen could target immunosuppressive lipid macrophages and improve ...

The acquisition follows Repare's decision this year to deprioritize its lead programs and lay off 75 percent of its workforce.

An investigator-developed drug has shown preclinical efficacy and is worth testing in clinical trials in aggressive breast ...

The firms will use the funds to integrate FYR's liquid biopsy platform in NuvOx's Phase II trial evaluating the oxygen therapeutic NanO₂ as a radiosensitizer.

CTX310 showed promising safety and efficacy in a small Phase I trial, according to data presented at the American Heart ...

NEW YORK – Nuvalent is angling for US approval in 2026 of its ALK inhibitor neladalkib for previously treated patients with ALK-positive non-small cell lung cancer after a pivotal Phase II trial ...

The FDA also approved Thermo Fisher's Oncomine Dx Target Test as a companion diagnostic to identify patients eligible for Hyrnuo.

The agency considered clinical trial data showing Redemplo can significantly reduce triglyceride levels in patients with familial chylomicronemia syndrome versus placebo.